Literature DB >> 19370352

Multi-system mitochondrial disorder with recurrent steroid-responsive eosinophilia.

Josef Finsterer1, Franz Höger.   

Abstract

Though mitochondrial disorders due to a respiratory chain defect may manifest with haematological abnormalities such as anaemia, neutropenia, or thrombocytopenia, recurrent steroid-responsive eosinophilia has not been reported as a manifestation of a mitochondrial disorder. In a polymorbid 65-year old female recurrent erythema, asthma, chronic bronchitis, gastritis with eosinophilic granuloma, recurrent episodes of hypereosinophilia, and polyarthralgia suggested Churg–Strauss syndrome, which was excluded upon absence of eosinophilic vasculitis on any of the biopsies. However, corticosteroids were effective for hypereosinophilia. In addition to the hypereosinophilic syndrome a mitochondrial disorder with multi-system affection was diagnosed upon the clinical presentation and a muscle biopsy indicative of a mitochondrial disorder. Hypereosinophilia was interpreted as a manifestation of the mitochondrial disorder after exclusion of various differentials. Mitochondrial disease may go along with marked eosinophilia mimicking Churg–Strauss syndrome. Steroids may be useful to resolve episodic eosinophilia but may be ineffective for other features of mitochondrial disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19370352     DOI: 10.1007/s00296-009-0915-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

1.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-2002. A 24-year-old woman with paresthesias and muscle cramps after a stay in Africa.

Authors:  Thomas B Nutman; Richard L Kradin
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

Review 2.  Recent progress in the pharmacotherapy of Churg-Strauss syndrome.

Authors:  Bernhard Hellmich; Wolfgang L Gross
Journal:  Expert Opin Pharmacother       Date:  2004-01       Impact factor: 3.889

Review 3.  Churg-Strauss syndrome.

Authors:  J G Lanham
Journal:  Br J Hosp Med       Date:  1992 May 6-19

Review 4.  Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.

Authors:  Jason Gotlib
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

5.  Mitochondrial respiratory chain dysfunction in various neuromuscular diseases.

Authors:  S Jongpiputvanich; T Sueblinvong; T Norapucsunton
Journal:  J Clin Neurosci       Date:  2005-05       Impact factor: 1.961

6.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis).

Authors:  A T Masi; G G Hunder; J T Lie; B A Michel; D A Bloch; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt
Journal:  Arthritis Rheum       Date:  1990-08

Review 7.  [Neuromuscular diseases with eosinophilia].

Authors:  J F Pellissier; D Figarella-Branger; G Serratrice
Journal:  Med Trop (Mars)       Date:  1998

Review 8.  [Churg-Strauss syndrome].

Authors:  V Cottin; J-F Cordier
Journal:  Rev Pneumol Clin       Date:  2003-02

Review 9.  Churg-Strauss syndrome.

Authors:  Imre Noth; Mary E Strek; Alan R Leff
Journal:  Lancet       Date:  2003-02-15       Impact factor: 79.321

Review 10.  Mitochondrial disorders.

Authors:  Massimo Zeviani
Journal:  Suppl Clin Neurophysiol       Date:  2004
View more
  3 in total

1.  Glucocorticoids for mitochondrial disorders.

Authors:  Josef Finsterer; Marlies Frank
Journal:  Singapore Med J       Date:  2015-02       Impact factor: 1.858

2.  Haematological abnormalities in mitochondrial disorders.

Authors:  Josef Finsterer; Marlies Frank
Journal:  Singapore Med J       Date:  2015-07       Impact factor: 1.858

Review 3.  The immune system as a driver of mitochondrial disease pathogenesis: a review of evidence.

Authors:  Allison Hanaford; Simon C Johnson
Journal:  Orphanet J Rare Dis       Date:  2022-09-02       Impact factor: 4.303

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.